09.03.24
Trinity Capital Inc., a provider of financial solutions to growth-oriented companies, has committed $35 million in equipment financing to ApiJect Systems Corp, a public-benefit medical technology company focused on prefilled, single-dose injection devices.
Based in Stamford, CT, ApiJect works with pharmaceutical companies to design rapidly scalable, cost-efficient drug delivery systems and then assists in manufacturing those devices. ApiJect aims to enable more liquid medicines and vaccines to effectively and safely reach more patients across the world.
"We are proud to support ApiJect on their mission to make injectable medicines and vaccines safer and accessible to everyone," said Melana Ferguson, Director, Equipment Finance at Trinity. "We look forward to working with their talented leadership team to accelerate the company's growth."
The new facility from Trinity will allow ApiJect to maximize the value of its hard assets to continue to scale operations and fund growth initiatives.
"We built the ApiJect injection platform to deliver an affordable prefilled option for most, if not all, injection medicines supported by a high volume manufacturing process and compact supply chain," said Jay Walker, Co-Founder, Executive Chairman, and CEO of ApiJect. "With Trinity's partnership, we are well positioned to expand our manufacturing capacity here in the U.S., file for regulatory approval for our initial device in the coming months, and partner with a growing list of pharma companies that want to use our injection technology with their drugs."
Based in Stamford, CT, ApiJect works with pharmaceutical companies to design rapidly scalable, cost-efficient drug delivery systems and then assists in manufacturing those devices. ApiJect aims to enable more liquid medicines and vaccines to effectively and safely reach more patients across the world.
"We are proud to support ApiJect on their mission to make injectable medicines and vaccines safer and accessible to everyone," said Melana Ferguson, Director, Equipment Finance at Trinity. "We look forward to working with their talented leadership team to accelerate the company's growth."
The new facility from Trinity will allow ApiJect to maximize the value of its hard assets to continue to scale operations and fund growth initiatives.
"We built the ApiJect injection platform to deliver an affordable prefilled option for most, if not all, injection medicines supported by a high volume manufacturing process and compact supply chain," said Jay Walker, Co-Founder, Executive Chairman, and CEO of ApiJect. "With Trinity's partnership, we are well positioned to expand our manufacturing capacity here in the U.S., file for regulatory approval for our initial device in the coming months, and partner with a growing list of pharma companies that want to use our injection technology with their drugs."
